Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUALIGHT-01: HB0025 plus chemotherapy as first-line treatment for advanced or recurrent pMMR endometrial cancer
CTR20262401Phase 3Active
- Sponsor
- Huabo Biopharm
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sotiburafusp alfa in endometrial cancer (EC), sponsored by Huabo Biopharm. Started Jun 2026; status: active.
02
Drugs
sotiburafusp alfa
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20262401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262401.